We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Innovative Gel Offers Revolutionary Treatment for Challenging Gastrointestinal Leaks

By HospiMedica International staff writers
Posted on 01 Dec 2023

Gastrointestinal leaks, medically referred to as enterocutaneous fistulas, are abnormal pathways between the gastrointestinal tract and the skin, often resulting from surgical complications. More...

This condition leads to the leakage of intestinal and stomach contents through to the skin, posing severe health threats such as skin damage, heightened infection risk, and high mortality rates, estimated at 15-20%. The primary treatment for this involves extensive surgery, aiming to restore bowel function, excise the fistula, and reconnect the bowel ends, followed by securing the abdominal wall. This underscores the pressing need for less invasive treatment options for sealing and healing these gastrointestinal leaks.

In a significant breakthrough, researchers at the Terasaki Institute for Biomedical Innovation (Los Angeles, CA, USA) have created an innovative adhesive gel designed to address gastrointestinal leaks. This novel treatment represents a substantial leap forward in managing a condition that has long presented challenges to both patients and healthcare providers. The gel is formulated from a combination of synthetic nanoparticles and gelatin altered with dopamine, enabling it to solidify rapidly upon injection. This rapid solidification forms a durable, adhesive structure, effectively sealing off the fistula and preventing further health complications while promoting healing.

The gel's standout feature is its ability to be easily injected and quickly form a stable structure, which is key in facilitating tissue regeneration and harmonizing with adjacent tissues. This attribute is especially beneficial in medical scenarios where precision and less invasive methods are crucial. Moreover, the gel has exhibited exceptional biocompatibility in animal studies. It encourages cell growth and the deposition of vital proteins for new tissue formation, essential aspects of the healing process. Importantly, the gel accomplishes these healing steps without causing fibrotic tissue formation, often a challenge in tissue repair methods. This research holds promise not only for the direct treatment of gastrointestinal leaks but also for broader applications in tissue engineering and regenerative medicine. The innovative approach and technologies developed through this research may pave the way for new therapeutic strategies across various medical fields.

Related Links:
Terasaki Institute 


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.